Protective - Metformin Use in Type 2 Diabetics
Metformin use substantially reducing risk (3 fold reduced mortality) of dying in Type 2s. ie. possibly reducing the effect of COVID-19.
There was an earlier French study also - Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
as well as one based in the US (looking at reduced risk in women)
Metformin use substantially reducing risk (3 fold reduced mortality) of dying in Type 2s. ie. possibly reducing the effect of COVID-19.
Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes
BackgroundCoronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality...
www.frontiersin.org
There was an earlier French study also - Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
as well as one based in the US (looking at reduced risk in women)
Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19
Importance Type 2 diabetes (T2DM) and obesity are significant risk factors for mortality in Covid19. Metformin has sex specific immunomodulatory effects which may elucidate treatment mechanisms in COVID-19. Objective: We sought to identify whether metformin reduced mortality from Covid19 and if...
www.medrxiv.org